ArticleACS chemical biology2026
Self-Avoiding Gamma Peptide Nucleic Acids for Selective Targeting of RNA Secondary Structures.
Article in ACS chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA molecules play essential roles in all aspects of cellular function, but their complex secondary and tertiary structures pose significant challenges for selective targeting. Traditional antisense strategies often avoid these structured regions, focused instead on unstructured sequences. In this study, we present an enhanced Self-Avoiding Molecular Recognition System designed to selectively recognize and bind structured RNA elements, offering an alternative approach for targeting biologically relevant RNA conformations with improved specificity and selectivity. This is achieved by incorporating established self-avoidance nucleobases (t and c) along with a deazapurine series (a and g)─designed to provide greater flexibility in fine-tuning binding affinity─into a conformationally preorganized gamma peptide nucleic acid backbone. Despite possessing self-complementary arms (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.